Definition
- Surgical removal of both ovaries (oophorectomy) and fallopian tubes (salpingectomy).
- Induces permanent menopause by eliminating ovarian estrogen production.
Clinical Role in Breast Cancer
1. Risk Reduction (Prophylactic Setting)
- In women with BRCA1/BRCA2 mutations or very high familial risk:
- BSO lowers ovarian cancer risk by ~80–90%.
- Also reduces breast cancer risk by ~50%, especially if performed before natural menopause.
- Typically recommended at age 35–40 (BRCA1) or 40–45 (BRCA2) after childbearing.
2. Therapeutic Setting (Hormone Receptor–Positive Breast Cancer)
- For premenopausal women with ER+/PR+ tumors:
- BSO provides ovarian suppression, similar to GnRH agonists (e.g., goserelin, leuprolide).
- Allows the use of aromatase inhibitors (letrozole, anastrozole, exemestane), which are only effective in postmenopausal women.
- Can be considered in metastatic disease to reduce estrogen-driven progression.
Pharmacist’s Considerations
| Aspect | Implication for Pharmacist |
|---|---|
| Hormonal effects | BSO → surgical menopause → ↓ estrogen, ↓ progesterone |
| Drug therapy impact | – Makes patient functionally postmenopausal → eligible for AI therapy – Tamoxifen still usable, but AI may be preferred |
| Alternative to BSO | GnRH agonists (goserelin, leuprolide) offer reversible suppression; BSO is permanent |
| Side effects | Immediate menopause: hot flashes, bone loss, vaginal dryness, ↑ CV risk |
| Supportive care | – Counsel on osteoporosis prevention (Ca, Vit D, bisphosphonates/denosumab if needed) – Manage menopausal symptoms (non-hormonal options preferred in breast cancer) |
| Drug monitoring | – If switching to AI after BSO, monitor bone density, lipids, CV risk – Avoid estrogen replacement therapy (contraindicated in breast cancer) |
Key Takeaways for Oncology Pharmacists
- BSO = irreversible ovarian suppression → converts premenopausal patient to postmenopausal status.
- Plays dual roles: risk-reducing surgery in BRCA carriers, and therapeutic ovarian ablation in ER+ breast cancer.
- Pharmacists should anticipate therapy changes (tamoxifen → AI), monitor bone health, and support management of menopausal symptoms.